Correction: Patel et al. Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA-LNP-Based Vaccines. Vaccines 2023, 11, 1224

Abstract

The authors would like to make the following corrections to this published paper [...].

Figure 1

LNP transfection curves across varying cell lines indicate variable levels of transfection, which improve with the addition of ApoE during transfection. (A) RSV-F protein expression efficiency in Vero, HeLA, HEp-2, A549, CaCo-2 and HepG2 cells was measured by counting percentage of cells positive for RSV-F protein. All cells were transfected for 16 ± 2 h with titration of LNPs starting with 200 ng dose of mRNA in media with 2% FBS. Data were fit using variable slope-four parameter logistics regression (4-PL) model in GraphPad Prism software (version: 6.0). (B–G) RSV-F protein expression efficiency following transfection with LNPs in media + 2%FBS, and media + 2%FBS supplemented with ApoE at 4 ug/mL. Hill-slope values [Y = Bottom + (Top − Bottom)/(1 + 10^((LogEC50-X) × Hill-slope)] from 4-PL regression are given for curves obtained with FBS supplemented with ApoE. (B) HeLa cells. (C) Vero cells. (D) Hep-2 cells. (E) CaCo-2 cells. (F) A549 cells. (G) HepG2 cells. (H) Representative immunofluorescence images of HepG2, Vero and A549 cells without ApoE and (I) with ApoE shown at 72 (top row) and 200 ng/mL (bottom row) of mRNA dose representing the bottom and top of the dose response curve, respectively.